Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Multi-Center, Controlled Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Commercially Available Meningococcal C Vaccine When Given as First, Third or Fourth Immunization to Children 32-40 Months of Age

NCT00310635 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00310635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00310635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Multi-Center, Controlled Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Commercially Available Meningococcal C Vaccine When Given as First, Third or Fourth Immunization to Children 32-40 Months of Age
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2005
Completion date
Not reported
Enrollment
241
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal infection